PD-1/PD-L1、TIM-3表达与食管癌临床病理特征及预后的关系

被引：14

作者：

刘凯 ^{[1
]}

刘燕 ^{[2
]}

黄莉 ^{[1
]}

刘凯 ^{[1
]}

机构：

[1] 新疆医科大学附属肿瘤医院头颈综合放射治疗科

[2] 新疆医科大学附属肿瘤医院胸腹放射治疗科

来源：

重庆医学 | 2022年 / 51卷 / 01期

关键词：

食管肿瘤; PD-1/PD-L1; TIM-3; 预后;

D O I：

暂无

中图分类号：

R735.1 [食管肿瘤];

学科分类号：

100214 ;

摘要：

目的探讨PD-1/PD-L1、TIM-3表达与食管癌临床病理特征及预后的关系。方法收集2008年1月1日至2012年12月31日该院收治的行根治性手术治疗的104例食管癌患者术后病理标本,采用免疫组织化学法检测PD-1、PD-L1、TIM-3表达,对比癌组织、癌旁组织相关蛋白表达情况,分析其与临床病理特征的关系,并采用Kaplan-Meier与Cox回归模型分析相关因素与无进展生存期(PFS)的关系。结果与癌旁组织比较,癌组织PD-1、PD-L1、TIM-3阳性表达例数均明显升高,差异均有统计学意义(P<0.05)。PD-1、PD-L1、TIM-3表达与性别、年龄、族别、吸烟史、饮酒史无关,病理TNM分期越高癌组织三者表达水平越高,且PD-1表达水平可能与病变部位有关,肿瘤浸润程度越深、伴淋巴结转移者PD-L1、TIM-3表达水平越高,TIM-3可能与肿瘤分化程度有关。随访至2014年12月31日,PD-1、TIM-3对患者中位PFS有影响,PD-L1对患者中位PFS无影响,PD-1、TIM-3高表达可能是患者不良预后的独立影响因素。结论癌组织PD-1、TIM-3表达可能影响患者预后。

引用

页码：65 / 69

页数：5

共 11 条

[1] TIM-3对食管癌细胞侵袭转移的作用机制及周期分布生物学分析 [J].

金昊 ;

沈兆坤 ;

许大伟 .

实用癌症杂志, 2019, 34 (01) :55-57

[2] The tumour immune microenvironment in oesophageal cancer [J].

Davern, Maria ;

Donlon, Noel E. ;

Power, Robert ;

Hayes, Conall ;

King, Ross ;

Dunne, Margaret R. ;

Reynolds, John V. .

BRITISH JOURNAL OF CANCER, 2021, 125 (04) :479-494

[3] Endoscopic resections for superficial esophageal squamous cell epithelial neoplasia: focus on histological discrepancies between biopsy and resected specimens [J].

Yang, Lang ;

Jin, Hua ;

Xie, Xiao-li ;

Cao, Yang-tian ;

Liu, Zhen-hua ;

Li, Na ;

Jin, Peng ;

He, Yu-qi ;

Sheng, Jian-qiu .

BMC GASTROENTEROLOGY, 2021, 21 (01)

[4] Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review [J].

Zhang, Wencheng ;

Wang, Ping ;

Pang, Qingsong .

ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (18)

[5] Role of surgery in multidisciplinary treatment strategies for locally advanced esophageal squamous cell carcinoma [J].

Saeki, Hiroshi ;

Sohda, Makoto ;

Sakai, Makoto ;

Sano, Akihiko ;

Shirabe, Ken .

ANNALS OF GASTROENTEROLOGICAL SURGERY, 2020, 4 (05) :490-497

[6]

Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.[J].Prabhakaran Kumar;Shikha Saini;Bellur S. Prabhakar.Seminars in Cancer Biology.2020, prepublish

[7] Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma [J].

Baba, Yoshifumi ;

Nomoto, Daichi ;

Okadome, Kazuo ;

Ishimoto, Takatsugu ;

Iwatsuki, Masaaki ;

Miyamoto, Yuji ;

Yoshida, Naoya ;

Baba, Hideo .

CANCER SCIENCE, 2020, 111 (09) :3132-3141

[8]

A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy.[J].Balamayoora Theivanthiran;Kathy S Evans;Nicholas C Devito;Michael Plebanek;Michael Sturdivant;Luke P Wachsmuth;April K S Salama;Yubin Kang;David Hsu;Justin M Balko;Douglas B Johnson;Mark Starr;Andrew Nixon;Alisha Holtzhausen;Brent A Hanks.Journal of Clinical Investigation.2020, 5

[9]

Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma..[J].Kim Ryul;Keam Bhumsuk;Kwon Dohee;Ock Chan-Young;Kim Miso;Kim Tae Min;Kim Hak Jae;Jeon Yoon Kyung;Park In Kyu;Kang Chang Hyun;Kim Dong-Wan;Kim Young Tae;Heo Dae Seog.World journal of gastroenterology.2016, 37

[10] Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma [J].

Hatogai, Ken ;

Kitano, Shigehisa ;

Fujii, Satoshi ;

Kojima, Takashi ;

Daiko, Hiroyuki ;

Nomura, Shogo ;

Yoshino, Takayuki ;

Ohtsu, Atsushi ;

Takiguchi, Yuichi ;

Doi, Toshihiko ;

Ochiai, Atsushi .

ONCOTARGET, 2016, 7 (30) :47252-47264

← 1 2 →